Browse Therapeutic Proteins based on alphabetical listing:
Peptides and proteins are known to have great therapeutic potentials against
several diseases and syndromes. They are an imperative part of the pharmaceutical
industry. Nowadays, numerous proteins are being studied as effective therapeutics
against a variety of diseases.
As protein-engineering technologies and regulatory frameworks evolve over
time, so do protein therapeutics. Optimized versions of existing therapies
can be achieved through better drug targeting as well as enhancing potency
and functionality. By understanding the mechanism of action, as well as
the structure-function relationship of a protein, rational design and engineering
strategies allow modification of its activity and introduction of new activities,
leading to customization of existing proteins or the generation of novel
therapeutics for specific clinical applications.
The term "biological target" is frequently used in pharmaceutical
research to describe the native protein in the body whose activity is modified
by a drug resulting in specific effects. Such effects may be a desirable
therapeutic effect or an unwanted adverse effect. In this context, the
biological target is often referred to as a drug target. The human genome,
completely sequenced in 2003, provides a vast source for drug target mining.
Any molecule that has implications in the pathogenesis of a disease is
a potential target for protein therapeutics. In contrast to small molecule
drugs that are able to diffuse across cell membranes, protein therapeutics
typically cannot traverse this cellular barrier due to their large size.
Therefore, they almost exclusively target cell surface receptors or extracellular
molecules. In recent years, researchers have also explored the possibility
of directing protein therapeutics to intracellular targets.
Protein therapeutics have three different modes of action based on the
pathology of a disease. First, if the disease is caused by unwanted extracellular
molecules such as cell metabolites or cell lysate, enzyme therapeutics
can degrade these targets. Second, if the disease is caused by a deficiency
in certain proteins, such as enzymes, protein therapeutics can be used
to replace them and restore an individual’s health. Third, if the disease
involves improper immune responses or dysregulated signaling pathways,
such as chronic inflammatory diseases, autoimmune diseases, infectious
diseases, and cancers, protein therapeutics act as inhibitors or activators
of cell surface receptors. Proteins are involved in these modes of actions
as a target, an interaction counterpart of the target, or an intermediate
of such interactions. Protein therapeutics show advantages such as higher
binding selectivity and specificity compared to small molecule drugs; therefore
they can target specific steps in disease pathology.
Figure 1. Classification of therapeutic proteins.
Basically, therapeutic proteins can be classified into four groups. Group
I: Therapeutic proteins with enzymatic or regulatory activity. Group II:
Therapeutic proteins with special targeting activity. Group III: Therapeutic
proteins as vaccines. Group IV: Therapeutic proteins as diagnostics.
Creative BioMart is devoted to discovery and manufacturing of recombinant
proteins, especially proteins that are of therapeutic interests. The quality
of our products are well known in both academic and industrial fields.
You can search proteins by drug target on our webpage. These proteins are
specific for research use and cannot be used as drugs directly. If you
have any trouble in finding products, please contact us directly.